OncoMatch/Clinical Trials/NCT05911217
A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer
Is NCT05911217 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies CT041 autologous CAR T-cell for pancreatic cancer.
Treatment: CT041 autologous CAR T-cell — An open-label, single-arm, multicenter, Phase Ib clinical trial to evaluate the efficacy and safety of CT041 Autologous CAR T Cell Injection after adjuvant chemotherapy in subjects with pancreatic cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Biomarker criteria
Required: CLDN18 positive (positive)
Disease stage
Required: Stage PTNM T1-3, N0-2 (pTNM)
Postoperative pathological stage (pTNM): T1-3, N0-2, M0
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: adjuvant therapy — postoperative
had received 3 months of standard adjuvant therapy
Cannot have received: neoadjuvant therapy
Prior neoadjuvant therapy for pancreatic cancer
Cannot have received: gene-modified cell therapy (CAR T, TCR T)
Previously received any gene-modified cell therapies (including CAR T, TCR T)
Lab requirements
Blood counts
Adequate organ function
Kidney function
Adequate organ function
Liver function
Adequate organ function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify